Altamira Therapeutics Ltd. Statistics
Share Statistics
Altamira Therapeutics Ltd. has 3.78M shares outstanding. The number of shares has increased by -52.5% in one year.
| Shares Outstanding | 3.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 68.67% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.76M |
| Failed to Deliver (FTD) Shares | 1.59K |
| FTD / Avg. Volume | 1.4% |
Short Selling Information
The latest short interest is 31.09K, so 0.82% of the outstanding shares have been sold short.
| Short Interest | 31.09K |
| Short % of Shares Out | 0.82% |
| Short % of Float | 0.83% |
| Short Ratio (days to cover) | 0.6 |
Valuation Ratios
The PE ratio is -0.2 and the forward PE ratio is -0.34.
| PE Ratio | -0.2 |
| Forward PE | -0.34 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.22 |
| P/FCF Ratio | -0.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Altamira Therapeutics Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.
| Current Ratio | 1.38 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.13% and return on capital (ROIC) is -90.21%.
| Return on Equity (ROE) | -1.13% |
| Return on Assets (ROA) | -0.94% |
| Return on Capital (ROIC) | -90.21% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -727.00K |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -88.14% in the last 52 weeks. The beta is 2.44, so Altamira Therapeutics Ltd.'s price volatility has been higher than the market average.
| Beta | 2.44 |
| 52-Week Price Change | -88.14% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 1.13 |
| Relative Strength Index (RSI) | 42.59 |
| Average Volume (20 Days) | 113.75K |
Income Statement
In the last 12 months, Altamira Therapeutics Ltd. had revenue of $0 and earned -$7.27M in profits. Earnings per share was $-14.81.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -5.92M |
| Net Income | -7.27M |
| EBITDA | -1.35M |
| EBIT | - |
| Earnings Per Share (EPS) | -14.81 |
Balance Sheet
The company has $617.41K in cash and $99.66K in debt, giving a net cash position of $517.75K.
| Cash & Cash Equivalents | 617.41K |
| Total Debt | 99.66K |
| Net Cash | 517.75K |
| Retained Earnings | -18.05M |
| Total Assets | 7.69M |
| Working Capital | 334.24K |
Cash Flow
In the last 12 months, operating cash flow was -$11.51M and capital expenditures $0, giving a free cash flow of -$11.51M.
| Operating Cash Flow | -11.51M |
| Capital Expenditures | 0 |
| Free Cash Flow | -11.51M |
| FCF Per Share | -23.44 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CYTO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3365.91% |
| FCF Yield | -686.91% |
Analyst Forecast
Currently there are no analyst rating for CYTO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 13, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Dec 13, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -3.55 |
| Piotroski F-Score | 3 |